| Delaying progression to type 2 diabetes among high-risk Spanish individuals is feasible in real-life primary healthcare settings using intensive lifestyle intervention B Costa, F Barrio, JJ Cabré, JL Pinol, X Cos, C Solé, B Bolíbar, J Basora, ... Diabetologia 55, 1319-1328, 2012 | 170 | 2012 |
| Prophylaxis versus pre-emptive treatment for infective and inflammatory complications of surgical third molar removal: a randomized, double-blind, placebo-controlled, clinical … JM Lacasa, JA Jiménez, V Ferrás, M Bossom, O Sóla-Morales, ... International journal of oral and maxillofacial surgery 36 (4), 321-327, 2007 | 161 | 2007 |
| Shifting from glucose diagnosis to the new HbA1c diagnosis reduces the capability of the Finnish Diabetes Risk Score (FINDRISC) to screen for glucose abnormalities within a … B Costa, F Barrio, JL Piñol, JJ Cabré, X Mundet, R Sagarra, ... BMC medicine 11, 1-12, 2013 | 103 | 2013 |
| Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders M Schlander, S Garattini, S Holm, P Kolominsky-Rabas, E Nord, ... Journal of comparative effectiveness research 3 (4), 399-422, 2014 | 76 | 2014 |
| Lifestyle interventions for diabetes mellitus type 2 prevention R Sagarra, B Costa, JJ Cabré, O Solà-Morales, F Barrio, ... Revista Clínica Española (English Edition) 214 (2), 59-68, 2014 | 43 | 2014 |
| Determining the value of medical technologies to treat ultra-rare disorders: a consensus statement M Schlander, S Garattini, P Kolominsky-Rabas, E Nord, U Persson, ... Journal of market access & health policy 4 (1), 33039, 2016 | 37 | 2016 |
| Feasibility and attractiveness of indication value-based pricing in key EU countries M Flume, M Bardou, S Capri, O Sola-Morales, D Cunningham, LA Levin, ... Journal of market access & health policy 4 (1), 30970, 2016 | 35 | 2016 |
| Mobile health strategies to tackle skin neglected tropical diseases with recommendations from innovative experiences: systematic review C Carrion, N Robles, O Sola-Morales, M Aymerich, JAR Postigo JMIR mHealth and uHealth 8 (12), e22478, 2020 | 34 | 2020 |
| European health data space—An opportunity now to grasp the future of data-driven healthcare D Horgan, M Hajduch, M Vrana, J Soderberg, N Hughes, MI Omar, JA Lal, ... Healthcare 10 (9), 1629, 2022 | 30 | 2022 |
| Approaches to manage ‘affordability’of high budget impact medicines in key EU countries M Flume, M Bardou, S Capri, O Sola-Morales, D Cunningham, LA Levin, ... Journal of market access & health policy 6 (1), 1478539, 2018 | 30 | 2018 |
| How can a joint European health technology assessment provide an ‘additional benefit’over the current standard of national assessments? Insights generated from a multi … E Julian, F Gianfrate, O Sola-Morales, P Mol, JF Bergmann, T Salmonson, ... Health economics review 12 (1), 30, 2022 | 23 | 2022 |
| Mobile applications in mood disorders and mental health: systematic search in apple app store and google play store and review of the literature S Eis, O Solà-Morales, A Duarte-Díaz, J Vidal-Alaball, L Perestelo-Pérez, ... International journal of environmental research and public health 19 (4), 2186, 2022 | 23 | 2022 |
| Coste-efectividad de la intervención sobre el estilo de vida para prevenir la diabetes tipo 2 R Sagarra, B Costa, JJ Cabré, O Solà-Morales, F Barrio, ... Revista Clínica Española 214 (2), 59-68, 2014 | 23 | 2014 |
| Defining innovation with respect to new medicines: a systematic review from a payer perspective O de Solà-Morales, D Cunningham, M Flume, PM Overton, N Shalet, ... International Journal of Technology Assessment in Health Care 34 (3), 224-240, 2018 | 22 | 2018 |
| Rationale and design of the PREDICE project: cost-effectiveness of type 2 diabetes prevention among high-risk Spanish individuals following lifestyle intervention in real-life … B Costa, JJ Cabré, R Sagarra, O Solà-Morales, F Barrio, JL Piñol, X Cos, ... BMC Public Health 11, 1-7, 2011 | 20 | 2011 |
| Addressing disparities and challenges in underserved patient populations with metastatic breast cancer in Europe E Vrdoljak, J Gligorov, L Wierinck, PF Conte, J De Grève, F Meunier, ... The Breast 55, 79-90, 2021 | 19 | 2021 |
| Perspectives to mitigate payer uncertainty in health technology assessment of novel oncology drugs O Solà-Morales, T Volmer, L Mantovani Journal of Market Access & Health Policy 7 (1), 1562861, 2019 | 19 | 2019 |
| A Double Blind, Placebo-Controlled, Randomised, Comparative Phase III Clinical Trial of Pharmacokinetically Enhanced Amoxicillin/Clavulanate 2000/125, as Prophylaxis or as … J Martínez Lacasa, J Jiménez, V Ferrás, C García-Rey, M Bosom, ... 43rd Annual ICAAC Chicago, 2003 | 19 | 2003 |
| DE-PLAN-CAT/PREDICE Research Group. Shifting from glucose diagnosis to the new HbA1c diagnosis reduces the capability of the Finnish Diabetes Risk Score (FINDRISC) to screen … B Costa, F Barrio, JL Piñol, JJ Cabré, X Mundet, R Sagarra, ... BMC Med 11, 45, 2013 | 17 | 2013 |
| Información, conocimiento y práctica sanitaria: la participación de los profesionales como pieza clave del engranaje P Adam, G Permanyer-Miralda, O Solà-Morales, J Canela-Soler Medicina Clínica 134, 10-15, 2010 | 16 | 2010 |
